BRUCE PLOESER: Open Payments
NPI 1447974183 · GOODYEAR, AZ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,124 in 58 payments from 17 companies in 2025. Trend: 2023 $905 · 2024 $1,213 · 2025 $1,124
Food & beverage: $1,124
| Company | Payments | Amount |
|---|---|---|
| Astellas Pharma US Inc | 8 | $205 |
| PFIZER INC. | 12 | $186 |
| Bayer Healthcare Pharmaceuticals Inc. | 10 | $151 |
| Novartis Pharmaceuticals Corporation | 4 | $102 |
| GlaxoSmithKline, LLC. | 3 | $66 |
| Lilly USA, LLC | 4 | $57 |
| Merck Sharp & Dohme LLC | 3 | $57 |
| AstraZeneca Pharmaceuticals LP | 3 | $49 |
| Corcept Therapeutics | 2 | $48 |
| Abbott Laboratories | 2 | $46 |
Products named: Veozah, Kerendia, ELIQUIS, LEQVIO, TRELEGY ELLIPTA, AIRSUPRA, Korlym, FREESTYLE LIBRE 3.
Industry payments across AZ — which companies pay providers there.
